Recommended Dose of Nivolumab in Metastatic Melanoma
For adults with metastatic cutaneous melanoma, nivolumab should be administered at 240 mg intravenously every 2 weeks OR 480 mg intravenously every 4 weeks as monotherapy, or 1 mg/kg combined with ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks. 1
Monotherapy Dosing Options
The FDA-approved dosing regimens for nivolumab monotherapy in metastatic melanoma include 1:
- 240 mg IV every 2 weeks, OR
- 480 mg IV every 4 weeks
Both flat-dose regimens are equivalent alternatives to the original weight-based dosing of 3 mg/kg every 2 weeks. Real-world evidence confirms that these flat-dose regimens demonstrate similar safety profiles and clinical outcomes compared to weight-based dosing 2, 3. The 480 mg every 4 weeks option offers greater convenience without compromising efficacy or safety.
Combination Therapy with Ipilimumab
For combination immunotherapy, the established regimen is 4, 1:
- Nivolumab 1 mg/kg + ipilimumab 3 mg/kg IV every 3 weeks for 4 doses
- Followed by nivolumab 240 mg every 2 weeks OR 480 mg every 4 weeks until disease progression or unacceptable toxicity
This combination demonstrated superior overall survival in the landmark CheckMate 067 trial, with 10-year data showing median overall survival of 71.9 months versus 36.9 months with nivolumab monotherapy and 19.9 months with ipilimumab alone 5. Approximately 31% of combination-treated patients achieved durable survival plateaus extending beyond 7 years.
Alternative Combination: Nivolumab Plus Relatlimab
An emerging option is 4:
- Nivolumab 480 mg + relatlimab 160 mg IV every 4 weeks until progression
This dual checkpoint blockade (PD-1 and LAG-3) offers an alternative to nivolumab-ipilimumab with potentially improved tolerability, though long-term comparative data are still maturing.
Clinical Decision Algorithm
Choose monotherapy (240 mg Q2W or 480 mg Q4W) when:
- Patient has favorable prognostic features
- Concerns about tolerability of combination therapy
- Older age or significant comorbidities limiting ability to manage immune-related adverse events
Choose combination therapy (nivolumab 1 mg/kg + ipilimumab 3 mg/kg × 4, then nivolumab maintenance) when:
- Aggressive disease requiring maximal response rates
- Patient can tolerate higher toxicity risk (grade 3-4 immune-related adverse events occur in ~40-50% with standard combination dosing) 6
- Younger, fit patients with good performance status
Critical Safety Considerations
The combination regimen carries significantly higher toxicity 7, 5:
- Grade 3-4 immune-related adverse events: 40-50% with combination vs. 11-13% with monotherapy
- Most common serious toxicities: colitis, hepatitis, pneumonitis, endocrinopathies
- Requires aggressive monitoring and early corticosteroid intervention
Important caveat: The original nivolumab 1 mg/kg + ipilimumab 3 mg/kg combination remains the FDA-approved and guideline-supported standard 4, 1. Alternative "flip-dose" regimens (nivolumab 3 mg/kg + ipilimumab 1 mg/kg) showed promise in neoadjuvant trials with reduced toxicity 6, but are not yet standard for metastatic disease.
Administration Details
- Infuse over 30 minutes for nivolumab monotherapy 1
- When combining with ipilimumab, administer nivolumab first, followed by ipilimumab on the same day
- Continue until disease progression, unacceptable toxicity, or up to 2 years in some protocols
- No dose adjustments needed for renal or hepatic impairment; manage toxicity with treatment delays and corticosteroids rather than dose reductions